Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

TScan Therapeutics (TCRX) Leases (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Leases for 6 consecutive years, with $57.7 million as the latest value for Q4 2025.

  • Quarterly Leases fell 10.28% to $57.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.7 million through Dec 2025, down 10.28% year-over-year, with the annual reading at $57.7 million for FY2025, 10.28% down from the prior year.
  • Leases for Q4 2025 was $57.7 million at TScan Therapeutics, down from $59.4 million in the prior quarter.
  • The five-year high for Leases was $64.4 million in Q4 2024, with the low at $4.4 million in Q3 2022.
  • Average Leases over 5 years is $43.1 million, with a median of $59.1 million recorded in 2022.
  • The sharpest move saw Leases decreased 25.08% in 2022, then skyrocketed 1240.18% in 2023.
  • Over 5 years, Leases stood at $5.5 million in 2021, then soared by 976.34% to $59.1 million in 2022, then rose by 7.43% to $63.5 million in 2023, then increased by 1.36% to $64.4 million in 2024, then fell by 10.28% to $57.7 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $57.7 million, $59.4 million, and $61.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.